T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: T3D-959, a dual PPAR-δ/PPAR γ nuclear receptor agonist and former diabetes drug candidate, has been repositioned as an Alzheimer's disease (AD)-modifying therapy. OBJECTIVE: This study examines the effectiveness and mechanisms of T3D-959's therapeutic effects using in vivo and ex vivo rat models of sporadic AD. METHODS: A sporadic AD model was generated by intracerebral (i.c.) administration of streptozotocin (STZ). Control and i.c. STZ treated rats were gavaged with saline or T3D-959 (0.3 to 3.0 mg/kg/day) for 28 days. Spatial learning and memory were evaluated using the Morris water maze test. Frontal lobe slice cultures generated 24 hours after i.c. STZ or vehicle were used to study early effects of T3D-959 (0.5-1.0 μM) on viability and molecular markers of AD. RESULTS: T3D-959 significantly improved spatial learning and memory in i.c STZ-treated rats. Mechanistically, T3D-959 significantly improved culture viability and brain morphology, reduced levels of oxidative stress and Aβ, and normalized expression of phospho-tau, choline acetyltransferase, and myelin-associated glycoprotein. Protective effects occurred even at the lowest tested dose of T3D-959. CONCLUSIONS: Pre-clinical proof of concept has been demonstrated that T3D-959 can improve multiple pathologies of AD resulting in significant improvements in cognitive function and molecular and biochemical indices of neurodegeneration. These results support the theses that (1) effective disease modification in AD can be achieved by targeting relevant nuclear receptors, and (2) treating AD as a metabolic disease has the potential to be disease remedial. A Phase 2a trial of T3D-959 in mild-to-moderate AD patients has been initiated (ClinicalTrials.gov identifier NCT02560753).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · cited 2×
“…(as seen in Type 2 diabetes) could contribute to brain insulin resistance by reducing brain insulin uptake and by raising brain levels of A (cid:4) , Tau-phosphorylation, oxidative stress, pro-inflammatory cytokines, advanced glycation end products, dyslipidemia, and apoptosis” [12, 13, 37–41].”
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 4×
“In fact, AD is now being called a form of diabetes that selectively or predominantly affects the brain, so-called ‘Type-3 Diabetes [1, 2].”
InfluentialAlzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158 · cited 3×
“In fact, AD is now being called a form of diabetes that selectively or predominantly affects the brain, so-called ‘Type-3 Diabetes [1, 2].”
Moloney, A. M., Griffin, R. J., Timmons, S., O’Connor, R., Ravid, R., & O’Neill, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.002 · Cited by 764 · cited 1×
“A growing body of evidence suggests that brain insulin resistance promotes or possibly triggers key defects in AD [2, 3, 11, 25–34] and is supported by observed changes in levels of insulin signaling molecules in AD forebrains and associated changes in memory [2, 11, 12, 27, 32, 34–36].”
Rivera, E. J., Goldin, A., Fulmer, N., Tavares, R., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8304 · Cited by 723 · cited 3×
“As A (cid:4) PP-A (cid:4) accumulation occurs early in the course of AD neurodegeneration and is linked to neuroinflamma-tion and stress [11, 63], most likely the anti-oxidant and insulin-sensitizing properties afforded by T3D-959 and PPAR agonists in general are responsible for this anti-AD effect.”
Baker, L. D., Cross, D. J., Minoshima, S., Belongia, D., Watson, G. S., & Craft, S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.225 · Cited by 639 · cited 2×
“…(as seen in Type 2 diabetes) could contribute to brain insulin resistance by reducing brain insulin uptake and by raising brain levels of A (cid:4) , Tau-phosphorylation, oxidative stress, pro-inflammatory cytokines, advanced glycation end products, dyslipidemia, and apoptosis” [12, 13, 37–41].”
Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells
Glass, C. K., & Saijo, K. (2010) · Nature Reviews Immunology · doi:10.1038/nri2748 · Cited by 619
Amyloid beta oligomers induce impairment of neuronal insulin receptors
Zhao, W., De Felice, F. G., Fernandez, S., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2008) · The FASEB Journal · doi:10.1096/fj.06-7703com · Cited by 587
Ma, Q.-L., Yang, F., Rosario, E. R., Ubeda, O. J., Beech, W., Gant, D. J., Chen, P. P., Hudspeth, B., Chen, C., Zhao, Y., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1071-09.2009 · Cited by 536 · cited 1×
“A growing body of evidence suggests that brain insulin resistance promotes or possibly triggers key defects in AD [2, 3, 11, 25–34] and is supported by observed changes in levels of insulin signaling molecules in AD forebrains and associated changes in memory [2, 11, 12, 27, 32, 34–36].”
How does diabetes accelerate Alzheimer disease pathology?
Sims-Robinson, C., Kim, B., Rosko, A., & Feldman, E. L. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.130 · Cited by 492 · cited 1×
“In addition to the aforementioned role of brain insulin resistance in AD, “insulin resistance in peripheral tissues (as seen in Type 2 diabetes) could contribute to brain insulin resistance by reducing brain insulin uptake and by raising brain levels of A , Tauphosphorylation, oxidative stress, pro-inflammatory cytoki…”
Cited by
The role of peroxisome proliferator-activated receptors (PPAR) in immune responses
Christofides, A., Konstantinidou, E., Jani, C., & Boussiotis, V. A. (2021) · Metabolism · doi:10.1016/j.metabol.2020.154338 · Cited by 720
Adamu, A., Li, S., Gao, F., & Xue, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1347987 · Cited by 564
de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
PPARs as Nuclear Receptors for Nutrient and Energy Metabolism
Hong, F., Pan, S., Guo, Y., Xu, P., & Zhai, Y. (2019) · Molecules · doi:10.3390/molecules24142545 · Cited by 233
Hong, F., Xu, P., & Zhai, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082189 · Cited by 139
Metadata
- Authors
- Tong, M., Deochand, C., Didsbury, J., & de la Monte, S. M.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2016-02-27
- Volume
- 51
- Issue
- 1
- Pages
- 123-138
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2254818940
- Cited by
- 55
- References
- 25
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.